ITRAQ-based quantitative proteomics reveals myoferlin as a novel prognostic predictor in pancreatic adenocarcinoma

Journal of Proteomics

Volumn 91, Issue , 2013, Pages 453-465

  Wang, Wan Sheng ^a,b   Liu, Xiao Hui ^a   Liu, Ling Xiao ^a,b   Lou, Wen Hui ^a   Jin, Da Yong ^a   Yang, Peng Yuan ^a   Wang, Xiao Lin ^a,b  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MEDICAL IMAGING   (China)

Author keywords

ITRAQ; Myoferlin; Pancreatic neoplasms; Prognosis; Proteomics

Indexed keywords

ISOBARIC TAGS FOR RELATIVE AND ABSOLUTE QUANTITATION; MEMBRANE PROTEIN; MYOFERLIN; REAGENT; UNCLASSIFIED DRUG;

ADULT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMING UNIT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; RNA INTERFERENCE; SURVIVAL; TANDEM MASS SPECTROMETRY; TISSUE DIFFERENTIATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ITRAQ; MYOFERLIN; PANCREATIC NEOPLASMS; PROGNOSIS; PROTEOMICS;

ADENOCARCINOMA; AGED; ANIMALS; APOPTOSIS; CALCIUM-BINDING PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MIDDLE AGED; MUSCLE PROTEINS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PHENOTYPE; PROGNOSIS; PROTEOMICS; RNA INTERFERENCE;

EID: 84883493436     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.06.032     Document Type: Article

References (32)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Wasif N., Ko C.Y., Farrell J., Wainberg Z., Hines O.J., Reber H., et al. Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging?. Ann Surg Oncol 2010, 17:2312-2320.
4. Zieske L.R. A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies. J Exp Bot 2006, 57:1501-1508.
5. Ralhan R., Desouza L.V., Matta A., Chandra Tripathi S., Ghanny S., Datta Gupta S., et al. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics 2008, 7:1162-1173.
6. Pierce A., Unwin R.D., Evans C.A., Griffiths S., Carney L., Zhang L., et al. Eight-channel iTRAQ enables comparison of the activity of six leukemogenic tyrosine kinases. Mol Cell Proteomics 2008, 7:853-863.
7. Doherty K.R., Cave A., Davis D.B., Delmonte A.J., Posey A., Earley J.U., et al. Normal myoblast fusion requires myoferlin. Development 2005, 132:5565-5575.
8. Doherty K.R., Demonbreun A.R., Wallace G.Q., Cave A., Posey A.D., Heretis K., et al. The endocytic recycling protein EHD2 interacts with myoferlin to regulate myoblast fusion. J Biol Chem 2008, 283:20252-20260.
9. Pontén F., Jirström K., Uhlen M. The human protein atlas-a tool for pathology. J Pathol 2008, 216:387-393.
10. Amatschek S., Koenig U., Auer H., Steinlein P., Pacher M., Gruenfelder A., et al. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 2004, 64:844-856.
11. Adam P.J., Boyd R., Tyson K.L., Fletcher G.C., Stamps A., Hudson L., et al. Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem 2003, 278:6482-6489.
12. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
13. Stec J., Wang J., Coombes K., Ayers M., Hoersch S., Gold D.L. Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J Mol Diagn 2005, 7:357-367.
14. DeNardo D.G., Kim H.T., Hilsenbeck S., Cuba V., Tsimelzon A., Brown P.H. Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol 2005, 19:362-378.
15. Labhart P., Karmakar S., Salicru E.M., Egan B.S., Alexiadis V., O'Malley B.W., et al. Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator. Proc Natl Acad Sci U S A 2005, 102:1339-1344.
16. Iacobuzio-Donahue C.A., Maitra A., Olsen M., Lowe A.W., van Heek N.T., Rosty C., et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 2003, 162:1151-1162.
17. Zhao C., Putnik M., Gustafsson J.A., Dahlman-Wright K. Microarray analysis of altered gene expression in ERbeta-overexpressing HEK293 cells. Endocrine 2009, 36:224-232.
18. Kristiansen G., Pilarsky C., Wissmann C., Kaiser S., Bruemmendorf T., Roepcke S., et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 2005, 205:359-376.
19. Skubitz A.P., Pambuccian S.E., Argenta P.A., Skubitz K.M. Differential gene expression identifies subgroups of ovarian carcinoma. Transl Res 2006, 148:223-248.
20. Hasegawa S., Furukawa Y., Li M., Satoh S., Kato T., Watanabe T., et al. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res 2002, 62:7012-7017.
21. Eisenberg M.C., Kim Y., Li R., Ackerman W.E., Kniss D.A., Friedman A. Mechanistic modeling of the effects of myoferlin on tumor cell invasion. Proc Natl Acad Sci U S A 2011, 108:20078-20083.
22. Li R., Ackerman W.E., Mihai C., Volakis L.I., Ghadiali S., Kniss D.A. Myoferlin depletion in breast cancer cells promotes mesenchymal to epithelial shape change and stalls invasion. PLoS One 2012, 7:e39766.
23. Leung C., Yu C., Lin M.I., Tognon C., Bernatchez P. Expression of myoferlin in human and murine carcinoma tumors: role in membrane repair, cell proliferation, and tumorigenesis. Am J Pathol 2013, 182:1900-1909.
24. Greene F.L., Page D.L., Fleming I.D., Fritz A., Balch C.M., Haller D.G. American joint committee on cancer: AJCC cancer staging manual 2002, Springer, New York, NY. 6th ed.
25. Chen Y., Lin M.C., Yao H., Wang H., Zhang A.Q., Yu J., et al. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 2007, 46:200-208.
26. Lee N.P., Leung K.W., Wo J.Y., Tam P.C., Yeung W.S., Luk J.M. Blockage of testicular connexins induced apoptosis in rat seminiferous epithelium. Apoptosis 2006, 11:1215-1229.
27. Bernatchez P.N., Acevedo L., Fernandez-Hernando C., Murata T., Chalouni C., Kim J., et al. Myoferlin regulates vascular endothelial growth factor receptor-2 stability and function. J Biol Chem 2007, 282:30745-30753.
28. Bernatchez P.N., Sharma A., Kodaman P., Sessa W.C. Myoferlin is critical for endocytosis in endothelial cells. Am J Physiol Cell Physiol 2009, 297:C484-C492.
29. Demonbreun A.R., Posey A.D., Heretis K., Swaggart K.A., Earley J.U., Pytel P., et al. Myoferlin is required for insulin-like growth factor response and muscle growth. FASEB J 2010, 24:1284-1295.
30. Tobita K., Kijima H., Dowaki S., Oida Y., Kashiwagi H., Ishii M., et al. Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma. Int J Oncol 2002, 21:1189-1195.
31. Tang D., Yuan Z., Xue X., Lu Z., Zhang Y., Wang H., et al. High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer. Int J Cancer 2012, 130:2337-2348.
32. Paron I., Berchtold S., Vörös J., Shamarla M., Erkan M., Höfler H., et al. Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway. PLoS One 2011, 6:e21684.